Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
icalcaprant
- Development stage
- Phase 2
- Lead developer
- AbbVie
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Icalcaprant (formerly CVL-354 or ABBV-1354) is a small molecule antagonist of the kappa opioid receptor (KOR) being developed for the treatment of psychiatric disorders, including major depressive disorder (MDD) and bipolar depression. By selectively blocking KOR, the drug aims to modulate the dysregulated dopamine and dynorphin systems associated with mood disorders, potentially reducing symptoms of depression and anhedonia. Originally developed by Cerevel Therapeutics, the asset was integrated into AbbVie's neuroscience portfolio following its $8.7 billion acquisition of Cerevel in 2024. Clinical development includes Phase 2 trials for bipolar depression and Phase 1 trials for major depressive disorder, with additional studies evaluating target occupancy at both kappa and mu opioid receptors in the brain.
- Other names
- icalcaprant
02
Targets
KOR (Kappa opioid receptor)MOR (Mu opioid receptor)
Beyond the preview
Go deeper on icalcaprant.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on icalcaprant.